Using ctDNA to Guide Immunotherapy in Limited-Stage Small-Cell Lung Cancer

Why Is This Study Important?

Limited-stage small-cell lung cancer (SCLC)is difficult to treat because of its aggressive course and high recurrence potential. The current standard is concurrent chemotherapy + radiotherapy. ADRIATIC showed that after chemoradiotherapy, maintenance immunotherapy (durvalumab) improves survival, establishing a new standard. However, patients do not benefit equally from immunotherapy. It is critical to identify who will benefit most from this costly treatment with potential side effects. This study investigates whether a blood biomarker, circulating tumor DNA (ctDNA) , can guide that decision.

🧪 What Is Circulating Tumor DNA (ctDNA)?

ctDNAis genetic material released by tumor cells into the blood. As a "liquid/key biopsy" tool, it can reflect tumor presence, burden, and treatment response . In this study, determining post-chemotherapy ctDNA status was considered a consolidation immunotherapy response predictor—a practical indicator of patients' potential response.

In the next section, we summarize the study's main numerical findings , including how early ctDNA positivity that persists shortens progression-free survival and which patients derive a clear benefit from immunotherapy . These topics are addressed with precise figures.

📊 Findings: ctDNA Informs Immunotherapy Decisions

Presented at the World Conference on Lung Cancer, this analysis from China's National Cancer Center was led by Dr. Nan Bi and included 144 limited-stage SCLC patients (100 chemoradiotherapy, 44 chemoradiotherapy + consolidation immunotherapy/serplulimab).

ctDNA assessment used a 139-gene lung cancer panel and sequencing at approximately 30,000× ultra-deep NGS coverage. No commercial brand name was provided, but because the collaborators included Nanjing Geneseeq Technology Inc. , the panel is thought to be one of this organization's liquid biopsy platforms.

🔎 Failure of Early ctDNA Clearance Predicts Poor Prognosis

In patients who remained ctDNA (+) after induction chemotherapy , progression-free survival (PFS) was dramatically shorter:

Interpretation: Persistent ctDNA despite treatment indicates residual disease and a high recurrence risk .

✅ Who Benefits From Immunotherapy?

• ctDNA (+) patients (after chemotherapy): Consolidation immunotherapy significantly prolongs PFS (HR 0.29; P = .013) and dramatically improves OS (HR 0.05; P < .001).
• ctDNA (–) patients: Immunotherapy provides no additional benefit (PFS: HR 1.30; OS: HR 1.14; not statistically significant).

Practical conclusion: Immunotherapy benefits the high-risk (ctDNA-positive) group; in the low-risk (ctDNA-negative) group, it may add no value.

🧩 ctDNA + Radiological Response = Three Risk Categories

Combining ctDNA status with radiological tumor shrinkage produces three groups:

• Low risk: ctDNA (–) + ≥60% shrinkage → excellent prognosis, limited additional immunotherapy benefit.
• High risk: ctDNA (+) + <60% shrinkage → significant immunotherapy benefits in PFS (HR 0.24) and OS (HR 0.06).
• Intermediate risk: The group in between; immunotherapy benefit remains uncertainand requires further study.

🏥 When Will It Enter Clinical Practice?

Although promising, these data are not yet sufficient for routine clinical practice . Prospective studies and stronger evidence are needed before ctDNA can be used as a guide to treatment selection .

🚀 Future Perspective

ctDNA is a strong candidate biomarker for personalized treatment . It may reveal immunotherapy's value, particularly in high-risk patients , while allowing low-risk patients to avoid unnecessary treatment and side effects .

In the future, "ctDNA-positive → immunotherapy needed" and "ctDNA-negative → immunotherapy unnecessary" approaches may become part of clinical algorithms .

🌟 Conclusion

This study opens a new chapter in SCLC treatment : the aim is to move beyond the same protocol for everyone toward biomarker-based personalized oncology. ctDNA could be a powerful key to giving the right treatment to the right patient at the right time.